U.S. FDA· FDA·· 4 hours agoPickScore77
FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions
In brief
On August 9, 2023, the FDA granted regular approval to pralsetinib (Gavreto, Genentech) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
Why it matters
ORR was 78% in treatment-naive patients and 63% after platinum chemotherapy, with median DOR of 13.4 and 38.8 months, letting readers compare efficacy across lines.
Source: U.S. FDA